vs
GENMAB A/S（GMAB）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是ROYAL GOLD INC的2.0倍（$925.0M vs $469.1M），ROYAL GOLD INC净利率更高（60.0% vs 36.3%，领先23.7%），ROYAL GOLD INC同比增速更快（142.6% vs 18.7%），GENMAB A/S自由现金流更多（$327.0M vs $278.9M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
GMAB vs RGLD — 直观对比
营收规模更大
GMAB
是对方的2.0倍
$469.1M
营收增速更快
RGLD
高出123.8%
18.7%
净利率更高
RGLD
高出23.7%
36.3%
自由现金流更多
GMAB
多$48.1M
$278.9M
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $469.1M |
| 净利润 | $336.0M | $281.7M |
| 毛利率 | 93.8% | — |
| 营业利润率 | 38.9% | 63.3% |
| 净利率 | 36.3% | 60.0% |
| 营收同比 | 18.7% | 142.6% |
| 净利润同比 | 65.5% | 147.7% |
| 每股收益（稀释后） | $5.42 | $3.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABRGLD
| Q1 26 | — | $469.1M | ||
| Q4 25 | — | $375.3M | ||
| Q3 25 | — | $252.1M | ||
| Q2 25 | $925.0M | $209.6M | ||
| Q1 25 | — | $193.4M | ||
| Q4 24 | — | $202.6M | ||
| Q3 24 | — | $193.8M | ||
| Q2 24 | $779.0M | $174.1M |
净利润GMABRGLD
| Q1 26 | — | $281.7M | ||
| Q4 25 | — | $93.6M | ||
| Q3 25 | — | $126.8M | ||
| Q2 25 | $336.0M | $132.3M | ||
| Q1 25 | — | $113.5M | ||
| Q4 24 | — | $107.4M | ||
| Q3 24 | — | $96.2M | ||
| Q2 24 | $203.0M | $81.2M |
毛利率GMABRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 73.6% | ||
| Q2 25 | 93.8% | 72.6% | ||
| Q1 25 | — | 69.4% | ||
| Q4 24 | — | 70.3% | ||
| Q3 24 | — | 66.6% | ||
| Q2 24 | 96.4% | 64.7% |
营业利润率GMABRGLD
| Q1 26 | — | 63.3% | ||
| Q4 25 | — | 56.2% | ||
| Q3 25 | — | 64.4% | ||
| Q2 25 | 38.9% | 67.7% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 65.9% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | 30.3% | 58.6% |
净利率GMABRGLD
| Q1 26 | — | 60.0% | ||
| Q4 25 | — | 24.9% | ||
| Q3 25 | — | 50.3% | ||
| Q2 25 | 36.3% | 63.1% | ||
| Q1 25 | — | 58.7% | ||
| Q4 24 | — | 53.0% | ||
| Q3 24 | — | 49.7% | ||
| Q2 24 | 26.1% | 46.6% |
每股收益（稀释后）GMABRGLD
| Q1 26 | — | $3.30 | ||
| Q4 25 | — | $1.04 | ||
| Q3 25 | — | $1.92 | ||
| Q2 25 | $5.42 | $2.01 | ||
| Q1 25 | — | $1.72 | ||
| Q4 24 | — | $1.63 | ||
| Q3 24 | — | $1.46 | ||
| Q2 24 | $3.13 | $1.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $234.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3B | $7.5B |
| 总资产 | $6.5B | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMABRGLD
| Q1 26 | — | $234.1M | ||
| Q4 25 | — | $233.7M | ||
| Q3 25 | — | $172.8M | ||
| Q2 25 | $1.3B | $248.2M | ||
| Q1 25 | — | $240.8M | ||
| Q4 24 | — | $195.5M | ||
| Q3 24 | — | $127.9M | ||
| Q2 24 | $622.0M | $74.2M |
总债务GMABRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M |
股东权益GMABRGLD
| Q1 26 | — | $7.5B | ||
| Q4 25 | — | $7.2B | ||
| Q3 25 | — | $3.4B | ||
| Q2 25 | $5.3B | $3.3B | ||
| Q1 25 | — | $3.2B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | $4.4B | $3.0B |
总资产GMABRGLD
| Q1 26 | — | $9.5B | ||
| Q4 25 | — | $9.5B | ||
| Q3 25 | — | $4.5B | ||
| Q2 25 | $6.5B | $3.6B | ||
| Q1 25 | — | $3.5B | ||
| Q4 24 | — | $3.4B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | $5.6B | $3.3B |
负债/权益比GMABRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $293.6M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $278.9M |
| 自由现金流率自由现金流/营收 | 35.4% | 59.4% |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | 1.04× | 1.04× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GMABRGLD
| Q1 26 | — | $293.6M | ||
| Q4 25 | — | $241.7M | ||
| Q3 25 | — | $174.0M | ||
| Q2 25 | $349.0M | $152.8M | ||
| Q1 25 | — | $136.4M | ||
| Q4 24 | — | $141.1M | ||
| Q3 24 | — | $136.7M | ||
| Q2 24 | $438.0M | $113.5M |
自由现金流GMABRGLD
| Q1 26 | — | $278.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $327.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $430.0M | — |
自由现金流率GMABRGLD
| Q1 26 | — | 59.4% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 55.2% | — |
资本支出强度GMABRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.0% | — |
现金转化率GMABRGLD
| Q1 26 | — | 1.04× | ||
| Q4 25 | — | 2.58× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | 1.04× | 1.15× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | 2.16× | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
RGLD
| North America | $258.0M | 55% |
| South and Central America | $110.2M | 23% |
| Europe, Middle East, Africa (EMEA) | $84.8M | 18% |
| Australia Pacific | $16.1M | 3% |
